# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jacqueline du Pré (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML039-SYN
- Date: 2026-10-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Thackeray-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six months: first 600 mg dose of ocrelizumab. **S**

## History of present illness

Ms. du Pré comes on the day of her first 600 mg dose of ocrelizumab, six months after starting treatment. She has had no relapse and no new symptoms. She played chamber music in public in August and last month, has a concerto booked for the spring, and gives master classes at a conservatory twice a month. Faint tingling in the left fingertips comes only after long practice. Fatigue is manageable with swimming and an after-lunch rest. She had influenza and COVID-19 vaccines a month ago. She asked when it would be safe to try for a baby, perhaps in a year or two. **S**

| Element | Detail |
|---|---|
| Disease activity | No relapse in six months; re-baseline MRI clear |
| Treatment | Ocrelizumab 600 mg today |
| Music | Performing chamber music; concerto booked; teaching master classes |
| Her question | Pregnancy in a year or two |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy manageable; no fever |
| Neurological | Positive | Faint tingling in the left fingertips after long practice only |
| Genitourinary | Negative | No urinary symptoms |
| Respiratory | Negative | No cough |
| Musculoskeletal | Negative | Neck stiffness after practice, better with stretching |
| Psychiatric | Negative | Happy to be playing; PHQ-9 3, GAD-7 3; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily **S**
- Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 63.8 kg; BMI 21.3 kg/m². All vital signs are synthetic.

Hemoglobin: 13.7 g/dL; White cell count: 6 10*3/uL; Lymphocytes: 1.4 10*3/uL; Platelets: 238 10*3/uL; Creatinine: 0.7 mg/dL; eGFR (CKD-EPI 2021): 121 mL/min/1.73 m²; ALT: 18 U/L; AST: 20 U/L; IgG: 930 mg/dL; IgM: 46 mg/dL; 25-hydroxyvitamin D: 38 ng/mL; Hepatitis B surface antibody: 6 m[IU]/mL (low); PHQ-9: 3; GAD-7: 3; Nine-hole peg test, right hand: 18.5 s; Nine-hole peg test, left hand: 19.5 s. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.4 g/dL at baseline, 13.7 g/dL at this visit **S**
- White cell count: 6.4 10*3/uL at baseline, 6 10*3/uL at this visit **S**
- Lymphocytes: 1.9 10*3/uL at baseline, 1.4 10*3/uL at this visit **S**
- Platelets: 246 10*3/uL at baseline, 238 10*3/uL at this visit **S**
- Creatinine: 0.72 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 117 mL/min/1.73 m² at baseline, 121 mL/min/1.73 m² at this visit **S**
- ALT: 16 U/L at baseline, 18 U/L at this visit **S**
- AST: 19 U/L at baseline, 20 U/L at this visit **S**
- Nine-hole peg test, right hand: 26 s at baseline, 18.5 s at this visit **S**
- Nine-hole peg test, left hand: 33.5 s at baseline, 19.5 s at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 63.8 kg; blood pressure 112/70 |
| Neurological | Vibration slightly reduced in the left fingertips only; otherwise normal. Nine-hole peg test 18.5 seconds right, 19.5 seconds left. EDSS 1.0 |
| Skin | No rash |
| Psychiatric | Bright and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Relapsing-remitting multiple sclerosis, on ocrelizumab** (G35.A). No evidence of disease activity at six months: no relapse, no new or enhancing lesions on the re-baseline MRI, and stable examination (EDSS 1.0, nine-hole peg 18.5 and 19.5 seconds). IgG 930 mg/dL is normal and IgM 46 mg/dL is low-normal, as is common on anti-CD20 therapy. Hepatitis B surface antibody is 6 mIU/mL after two doses, not protective, because the second dose came after B-cell depletion. Pregnancy: ocrelizumab does not need to be stopped long in advance; the usual plan is to try to conceive a few months after a dose, stopping contraception at that point, and to restart treatment after delivery; breastfeeding is possible. **S**
   - Ocrelizumab 600 mg today, then every six months.
   - Blood count and immunoglobulins before each dose; MRI of the brain yearly.
   - Hepatitis B: counsel on avoiding exposure; a booster is unlikely to work while B cells are depleted, so it is deferred and the antibody rechecked if treatment changes.
   - Preconception visit with the neurologist when she is ready.
2. **Vitamin D deficiency** (E55.9). 38 ng/mL on cholecalciferol. **S**
   - Continue cholecalciferol 4000 units daily.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with lymphocytes | Before each ocrelizumab dose | Completed today | Hemoglobin 13.7 g/dL, white cells 6.0, lymphocytes 1.4, platelets 238 |
| Laboratory | Immunoglobulins (IgG, IgM) | At baseline and before each ocrelizumab dose | Completed today | IgG 930 mg/dL, IgM 46 mg/dL (low-normal) |
| Laboratory | Kidney and liver tests | Before each dose | Completed today | Creatinine 0.70 mg/dL, eGFR 121; ALT 18 U/L, AST 20 U/L |
| Laboratory | 25-hydroxyvitamin D | Every six to twelve months on replacement | Completed today | 38 ng/mL |
| Laboratory | Hepatitis B surface antibody after vaccination | One to two months after the last dose | Completed today | 6 mIU/mL, not protective; drawn late (deviation recorded at the fourth visit) |
| Laboratory | Pregnancy test | Before each ocrelizumab dose | Completed today | Urine pregnancy test negative |
| Imaging | MRI of the brain | Yearly on treatment | Due | Next about a year after the re-baseline scan |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 18.5 seconds right, 19.5 seconds left |
| Examination | Neurological examination and EDSS | Each review | Completed today | EDSS 1.0; no change |
| Medication safety | Infections on anti-CD20 therapy | Each review | Completed today | None since June |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 3 (item 9 scored 0), GAD-7 3 |
| Self-management | Pregnancy planning | At each review in women who may become pregnant | Completed today | Plan to conceive a few months after a dose, with a preconception visit |
| Self-management | Fatigue: causes and management | Each review | Completed today | Managed with exercise and pacing |

## Goal progress

- MRI of the brain and spine within one week and a neurology diagnosis within three weeks. Outcome by 2026-03-23: MRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks. **S**
- High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations. Outcome by 2026-04-27: Ocrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given first. **S**
- Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed. Outcome by 2026-07-13: 19.0 seconds right and 20.5 seconds left at three months; practicing three hours a day. **S**
- No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression). Outcome by 2026-10-12: No relapse; re-baseline MRI with no new or enhancing lesions; examination stable. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more. Outcome by 2026-07-13: 34 ng/mL after 16 weeks of cholecalciferol. **S**
- PHQ-9 below 10 throughout. Outcome by 2026-10-12: PHQ-9 between 3 and 7. **S**

## Guideline basis

- Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018), American Academy of Neurology
- Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018), European Committee for Treatment and Research in Multiple Sclerosis / European Academy of Neurology
- Multiple sclerosis in adults: management (NICE guideline NG220) (2022), National Institute for Health and Care Excellence
- Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021), The Lancet Neurology
- Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019), American Academy of Neurology

## Follow-up

- Ocrelizumab every six months; MRI of the brain in about nine months; primary care review in six months; preconception visit when she is ready. **S**

